| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 13 Nov 2026 |
Form 4: Formela Jean Francois, Director
Sold 26,587 shares ($401K) · Sold 40,045 shares ($573K) |
| 12 Nov 2026 | 144 |
| 12 Nov 2026 | 144 |
| 12 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 | 10-Q |
| 05 Nov 2026 |
8-K: Termination of a Material Definitive Agreement; Results of Operations and Financial Condition
Ended third quarter 2026 with $124.8 million in cash, cash equivalents and marketable securities, supporting a cash runway into the second half of 2028 |
| 27 Oct 2026 | SCHEDULE 13G/A |
| 26 Oct 2026 |
Form 4: Lynx1 Capital Management Lp, 10% owner and 1 other
Bought 52,175 shares ($559K) · Bought 2,510 shares ($30.4K) · Bought 25,124 shares ($295K) |
| 22 Oct 2026 |
8-K: Other Events
Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency |
| 05 Oct 2026 |
8-K: Other Events
Initiated a Phase 1/2 clinical trial to enroll healthy volunteers and patients with Urea Cycle Disorders of any mutational background |
| 15 Sep 2026 |
Form 4: Formela Jean Francois, Director
Sold 10,200 shares ($143K) · Sold 38,490 shares ($543K) |
| 14 Sep 2026 | 144 |
| 14 Sep 2026 | 144 |
| 14 Sep 2026 |
Form 4: Dolan Oliver, Senior Vice President, Finance
Sold 5 shares ($68.6) |
| 11 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
| 11 Sep 2026 | 144 |
| 10 Sep 2026 |
Form 4: Dolan Oliver, Senior Vice President, Finance
Sold 7,347 shares ($99.3K) · Sold 6 shares ($81.6) |
| 09 Sep 2026 | 144 |
Loading...